Eczema (Atopic Dermatitis) Clinical Trials in Columbus
View 30 new treatments for Eczema (Atopic Dermatitis) in Columbus, OH. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Nemolizumab for Eczema
Galderma Clinic, Dublin + 2 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Lebrikizumab for Eczema
Eli Lilly Clinic, Bexley + 3 more
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Upadacitinib + Topical Corticosteroids for Eczema
AbbVie Clinic, Columbus + 2 more
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Rocatinlimab for Eczema
Amgen Clinic, Columbus + 1 more
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Amlitelimab for Atopic Dermatitis (COAST 2)
Sanofi Clinic, Bexley + 1 more
This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, Bexley + 3 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Pfizer CT.gov Call Center
Study Director
Linerixibat for Itching in Cholangitis
GlaxoSmithKline Clinic, Columbus + 1 more
This trial is testing a medication called linerixibat to see if it can help reduce severe itching in people with a liver condition called Primary Biliary Cholangitis (PBC). The study will compare the effects of linerixibat to check its effectiveness and safety.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
GSK Clinical Trials
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Springfield + 1 more
This trial is testing a medication called rocatinlimab to see if it changes how well people respond to tetanus and meningococcal vaccines by measuring antibody levels.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Bexley + 1 more
This trial tests a new drug called rocatinlimab combined with common skin treatments on patients with eczema. The goal is to see if this combination works better than standard treatments alone by calming the immune system to reduce symptoms like redness and itching.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director
Ruxolitinib Cream for Prurigo Nodularis
Incyte Clinic, Dublin + 1 more
This trial tests the safety and tolerability of a cream for people with Prurigo Nodularis, a condition with itchy skin nodules. The cream works by blocking enzymes that cause inflammation and itching. It has been previously tested for its effects in conditions like atopic dermatitis.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Page 1 of 3
Frequently Asked Questions
Explore related conditions